The Premier Meeting in the Field of Psychopharmacology

The meeting brings together over 800 academic and industry investigators, research pharmacists, and clinicians, including competitively selected New Investigator awardees. ASCP is joined by federal partners, the National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), the National Institute on Alcohol Abuse and Alcoholism, (NIAAA) and the Food and Drug Administration (FDA) to organize a program that emphasizes the presentation of information that has not been previously published or presented.

Sponsorships for the 2024 ASCP Annual Meeting are now open.

Thank you, 2023 Sponsors!


840 total attendees in 2023

The 2023 ASCP Annual Meeting was the first year sponsorships were accepted and it was a true success. Thank you to all of our wonderful sponsors for your support!





Gold Sponsors

Silver Sponsors

Global Representation

Countries Represented

States Represented

Attendee Satisfaction


Thought the program was current and relevant to professional practice or research.


Feel confident in their application of the material presented to their practice or research.


Felt the 2023 Annual Meeting boosted their confidence in patient consultation and/or research they are conducting.


Believe the range of scientific topics offered at the 2023 Annual Meeting is better than most of the other meetings they attend.


Said the conference staff provided quality service.

Submissions are open for the 2024 ASCP Annual Meeting.

Listed below are the submissions accepted for the ASCP Annual Meetings.



  • Poster Presentation – Poster board presentation in a general session.
    Deadline: January 29, 2024
  • Individual Research Report – Selected by the Program Committee, these are 10 minute oral presentation with 5 minutes Q&A from the audience.
    Deadline: January 29, 2024
  • Pharmaceutical Pipeline Presentations – A Pharmaceutical Pipeline report will be a 10 minute presentation and will also have the opportunity to present their research as a poster presentation. A Pharmaceutical Pipeline submission should include those with early clinical data (Phase 1 and 2) on any CNS compound for which Phase 3 data has not been presented. The goal is to generate enthusiasm for the many novel compounds under exploration, most of which have not reached Phase 3. This is not to exclude presentations of clinical data on compounds currently in Phase 3 targeted to truly untested mechanisms since such data would also be of great interest.
    Deadline: February 20, 2024

  • Late-Breaking Posters– Late-breaking science included in the poster session.
  • Panel Sessions* – Have a Chair, a minimum of 3 Speakers but no more than 4 speakers, and a discussant. A co-chair is optional. Panel sessions are 1.5 hours in length.
    Deadline: November 13, 2023
  • Workshop Sessions* – Integrative session with a chair and no more than 8 participants. A discussant and co-chair is optional. Workshop sessions are 2 hours in length.
    Deadline: November 13, 2023